Search clinical trials for: ER Paliperidone

Total 834 results

Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese Volunteers

Schizophrenia
Janssen Cilag N.V./S.A.

Completed

IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation

Psychomotor Agitation | Acute Disease

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia

Schizophrenia
Janssen Korea, Ltd., Korea

Completed

PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia (PANDORA)

Schizophrenia

Korea, Republic of
Janssen-Cilag Turkey

Completed

A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia

Schizophrenia

Turkey
Chonnam National University Hospital
Janssen Korea, Ltd., Korea; Ministry of Health, Republic of Korea

Completed

Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia

Schizophrenia

Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia

Schizophrenia
Centre Hospitalier de Meaux
Ministry of Health, France

Completed

Selenium, as Sodium Selenite, in the Treatment of Septic Shock

Septic Shock | Severe Sepsis

France
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder

Mood Disorders | Bipolar Disorder

United States, Taiwan, Russian Federation, Turkey, Ukraine, Greece, Korea, Republic of, Lithuania
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease

Psychotic Disorders | Schizophrenia | Schizoaffective Disorder

United States
Janssen-Cilag G.m.b.H

Terminated

A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls

Schizophrenia

Germany
Chonbuk National University Hospital
AstraZeneca; Sanofi-Synthelabo; Janssen Korea, Ltd., Korea; Korea Otsuka Pharmaceutical...

Completed

Different Safety Profile of Risperidone and Paliperidone Extended-release

Schizophrenia

Korea, Republic of
Ortho-McNeil Janssen Scientific Affairs, LLC

Terminated

The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With Schizophrenia (POST)

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS Paliperidone

Schizophrenia
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Withdrawn

To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS

Multiple Sclerosis | Sperm

United States
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia

Schizophrenia
Rhode Island Hospital

Completed

Improving Emotion Regulation Skills Among Adolescents Attempting to Lose Weight

Overweight and Obesity

United States
Janssen Research & Development, LLC

Completed

An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia

Schizophrenia

Ukraine, United States, Spain, India, Romania, Russian Federation, Slovakia
Janssen Scientific Affairs, LLC

Completed

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (DREaM)

Psychotic Disorders | Schizophrenia

United States, Brazil, Mexico
TaiRx, Inc.

Completed

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients

Advanced Cancer

Taiwan
Columbia University
Biolase Inc

Active, not recruiting

Peri-implantitis Treatment: Clinical Results of Conventional Treatment vs. the Addition of Biolase

Peri-Implantitis

United States
HealthPartners Institute

Terminated

Outreach-ER: A Dementia Care Intervention Program

Dementia

United States
Uppsala University

Recruiting

Emotion Regulation Training for Adolescents With ADHD

ADHD | Emotion Regulation | Attention Deficit Disorder With Hyperactivity

Sweden
Jewish General Hospital

Recruiting

Emergency Room Visits and Older Patients (ER2) (ER2)

Emergencies | Length of Stay

Canada
Medical University of South Carolina
Georgia State University

Completed

PTSD Treatment and Emotion Regulation Skills Training for Veterans With Military Sexual Trauma (PE+ER) (PE+ER)

Anxiety Disorders | Stress Disorders, Post-Traumatic | Mental Disorder | Traumatic Stress Disorder

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder

Bipolar Disorder

United States, China, Germany, Bulgaria, Costa Rica, France, India, Malaysia, Panama, Poland, Romania, Russian Federation, Serbia, South Africa, Turkey, Ukraine
Member Companies of the Opioid PMR Consortium

Terminated

Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain

Opioid-Related Disorders | Drug Abuse | Opiate Addiction | Narcotic Abuse

United States
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia

Schizophrenia

Japan
Asieris Pharmaceuticals (AUS) Pty Ltd.

Completed

A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets

Bladder Cancer

Australia
Washington State University
American Society for Pain Management Nursing

Recruiting

Empowered Relief Delivered by Nurses (ERA)

Pain, Chronic

United States
National Institute of Mental Health (NIMH)

Completed

Assessment of [11C]ER176 to Image Translocator Protein in Brain and Whole Body of Healthy People

Pharmacokinetics | Adult

United States
Korea University Anam Hospital

Completed

YSGG Application in Periodontal Treatment

Periodontal Diseases

Korea, Republic of
Lotus Pharmaceutical

Completed

Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine

Migraine Without Aura | Migraine With Aura

Taiwan
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
Janssen-Cilag International NV

Completed

A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia

Schizophrenia

Spain, Argentina, Romania, South Africa, Turkey, Greece, Lithuania, Slovakia, Latvia, Estonia, France, Egypt, Lebanon, Jordan
Kowa Research Institute, Inc.

Completed

Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Compared to K-877-IR

Dyslipidemia

United States
Ultragenyx Pharmaceutical Inc

Completed

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy (HIBM)

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia

Schizophrenia

United States, Ukraine, Taiwan, Malaysia, Romania, Russian Federation, Serbia, Korea, Republic of
Xian-Janssen Pharmaceutical Ltd.

Completed

A Randomized, Active-controlled, Double-blind, Parallel-Goup Study of the Efficacy and Safety of Extended Release(ER) Paliperidone in the Treatment of Schizophrenia

Acute Schizophrenia

China
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Completed

Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia

Schizophrenia

United States
Tehran University of Medical Sciences

Completed

Half-Dose Depot Triptorelin Versus Reduced-Dose Daily Buserelin

Infertility

Iran, Islamic Republic of
Lars Adolfsson

Recruiting

Non-operative Treatment in Sweden of Proximal Humeral Fractures (NOSWEPH)

Proximal Humeral Fracture

Sweden
University Hospital Inselspital, Berne

Completed

Feasibility of REBOA in Refractory Cardiac Arrest

Heart Arrest

Switzerland
University of British Columbia
Children's & Women's Health Centre of British Columbia

Terminated

Sup-ER Protocol RCT

Birth Related Brachial Plexus Injury | Obstetrical Brachial Plexus Palsy

Canada
Assiut University

Not yet recruiting

Transcranial Ultrasound and Transcranial Doppler in Diagnosis and Detection of Outcome in Infants With Neurological Diseases

Trancranial Doppler
Ain Shams University

Completed

Efficacy of Er: YSGG Laser in Treatment of Peri-implantitis

Peri-Implantitis

Egypt
Rawalpindi Medical College

Completed

Enhancing Triage Accuracy: A Clinical Audit of the Manchester Triage System Implementation

Triage

Pakistan
Chen Laser Institute

Completed

Clinical Study of Laser Analgesia in Cavity Preparations Using the Er,Cr:YSGG Laser

Tooth Pain

United States
University of Zagreb

Completed

Comparison Between Two Different High Power Ablative Lasers in the Treatment of Oral Leukoplakia

Leukoplakic Lesions
Boehringer Ingelheim

Completed

Bioavailability of Four Oral Prototype Extended Release Formulations With BI 11634 in Healthy Male Volunteers

Healthy

3

Subscribe